• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

    2/15/23 8:00:00 AM ET
    $AGRX
    $PG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $AGRX alert in real time by email

    Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team

    GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.

    Appointment of Ernie De Paloantonio to Chief Financial Officer Further Strengthens CPSI's Leadership Team

    Ernie brings over 30 years of financial and business experience in the pharmaceutical industry including both private and public commercial and manufacturing companies. Most recently, he was Chief Financial Officer of Journey Medical Corporation, a commercial stage dermatology company. Prior to that, he held several leadership positions throughout his career including Chief Financial Officer at Teligent, Inc., a specialty generic pharmaceutical company, Fortovia Therapeutics Inc., a privately held healthcare company, Chief Financial Officer, Secretary and Treasurer of BioDelivery Sciences International, Inc., a public specialty pharmaceutical company and Chief Financial Officer of CorePharma LLC, a privately held specialty generic company.

    As CFO, Ernie will have responsibility for both finance and information technology.

    "I am pleased to be able to work with Ernie again as we look to grow this promising specialty development and manufacturing business. Ernie will bring his over thirty years of financial experience across a spectrum of pharmaceutical companies to help drive the growth of Corium Pharma Solutions. He will play an instrumental role working closely with myself, members of the leadership team, and our investors on our long-term growth strategy and its execution," said Mark Sirgo, CEO of CPSI, in making the announcement.

    Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike. CPSI currently manufactures a variety of over the counter and prescription products, including Proctor & Gamble Co's (NYSE:PG) entire Crest Whitestrips franchise, Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Twirla®, and Corium, LLC's ("Corium") ADLARITY®, a once-weekly, transdermal donepezil patch.

    About Corium Pharma Solutions

    Headquartered in Grand Rapids, Michigan, Corium Pharma Solutions is a leading, full-service contract development and manufacturing organization specializing in novel drug and consumer product delivery technologies. With a track record spanning nearly 30 years, the company offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and proprietary drug delivery technologies, CORPLEX™ and MICROCOR®. Corium Pharma Solutions is jointly owned by B-FLEXION and Webster Equity Partners. Prior to the CPSI transaction with Webster Equity Partners in October 2022, Gurnet Point Capital, an affiliate of B-Flexion, led the original investment in Corium Pharma Solutions through a take-private transaction in October 2018.

    About Gurnet Point Capital & B-FLEXION

    Gurnet Point Capital, an affiliate of B-FLEXION, is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point's team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.

    www.gurnetpointcapital.com/

    B-FLEXION is a private, entrepreneurial investment firm, partnering with sophisticated capital to meet the shared goal of delivering exceptional value over the generations, while also contributing positively to society. The company oversees growth-oriented operating businesses and asset managers, always with an 'active owner' philosophy. B-FLEXION invests across a wide range of industries, including healthcare. Gurnet Point Capital, an affiliate of B-FLEXION, leads B-FLEXION's de-risked life sciences investment strategy.

    https://www.bflexion.com/

    About Webster Equity Partners

    Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. https://websterequitypartners.com/

    Contact

    Gartman PR

    (202) 413-4226

    Cision View original content:https://www.prnewswire.com/news-releases/corium-pharma-solutions-names-ernie-de-paolantonio-as-chief-financial-officer-301746886.html

    SOURCE Corium Pharma Solutions Inc.

    Get the next $AGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $PG

    CompanyDatePrice TargetRatingAnalyst
    Procter & Gamble Company
    $PG
    6/12/2026$156.00Mkt Perform
    Bernstein
    Procter & Gamble Company
    $PG
    3/24/2026Buy → Hold
    Erste Group
    Procter & Gamble Company
    $PG
    2/18/2026Hold → Buy
    Erste Group
    Procter & Gamble Company
    $PG
    1/27/2026$156.00Buy → Hold
    TD Cowen
    Procter & Gamble Company
    $PG
    1/23/2026$165.00Neutral → Overweight
    Analyst
    Procter & Gamble Company
    $PG
    1/7/2026$150.00Neutral
    Piper Sandler
    Procter & Gamble Company
    $PG
    12/17/2025$179.00Hold → Buy
    Jefferies
    Procter & Gamble Company
    $PG
    12/8/2025$153.00 → $151.00Equal Weight
    Barclays
    More analyst ratings

    $AGRX
    $PG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Procter & Gamble with a new price target

    Bernstein initiated coverage of Procter & Gamble with a rating of Mkt Perform and set a new price target of $156.00

    6/12/26 8:39:29 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Procter & Gamble downgraded by Erste Group

    Erste Group downgraded Procter & Gamble from Buy to Hold

    3/24/26 12:34:46 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Procter & Gamble upgraded by Erste Group

    Erste Group upgraded Procter & Gamble from Hold to Buy

    2/18/26 9:43:08 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    SEC Filings

    View All

    Procter & Gamble Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    7/14/26 4:19:08 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 11-K filed by Procter & Gamble Company

    11-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    6/4/26 1:58:20 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SD filed by Procter & Gamble Company

    SD - PROCTER & GAMBLE Co (0000080424) (Filer)

    5/27/26 10:11:12 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Swiffer Lemon Duster Delivers the Fresh Scent of Clean with No Spray Required

    Swiffer’s newest innovation helps Trap + Lock™ dust while adding joy to one of the most avoided household chores According to consumer research, more than 4 in 10 Americans say they dislike or hate dusting1, making it one of the most dreaded chores around the home. With the new Swiffer Lemon Dusters, Swiffer is transforming a routine people often avoid into a cleaning experience that feels more refreshing, satisfying and rewarding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722644096/en/Swiffer Heavy Duty 6 ft Extendable Duster Kit with Lemon-Scented Refills Designed to tackle one of consumers' least favorite household

    7/22/26 10:01:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Head & Shoulders Debuts USAG Partnership at 2026 U.S. Classic

    --The Official Shampoo of USA Gymnastics brings the "High Stakes. No Flakes." Experience to Hartford, CT-- The multi-year, multi-brand partnership between Procter & Gamble and USA Gymnastics (USAG) will officially debut with Head & Shoulders, the Official Shampoo of USA Gymnastics, at the 2026 U.S. Classic in Hartford, CT (July 17–18). A long-standing global Olympic and Paralympic Partner, P&G launched the USAG partnership in February when they celebrated the conclusion of The Olympic and Paralympic Winter Games Milano Cortina 2026 and generated excitement for The Olympic and Paralympic Games LA 2028 when the Games come back to the U.S. for the first time in over 25 years. Head & Should

    7/16/26 9:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Declares Quarterly Dividend, July 2026

    The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0885 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after August 17, 2026 to Common Stock shareowners of record at the close of business on July 24, 2026, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on July 24, 2026. P&G has been paying a dividend for 136 consecutive years since its incorporation in 1890 and has increased its dividend for 70 consecutive years. This reinforces our commitment to return cash to shareowners, many of who

    7/14/26 4:15:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Santos De Azevedo Juliana Monteiro claimed ownership of 19,693 shares (SEC Form 3)

    3/A - PROCTER & GAMBLE Co (0000080424) (Issuer)

    7/10/26 2:29:28 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    New insider Santos De Azevedo Juliana Monteiro claimed ownership of 19,693 shares (SEC Form 3)

    3 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    7/10/26 11:14:54 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Portman Robert Jones was granted 51 shares, increasing direct ownership by 1.00% to 5,155 units (SEC Form 4)

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    6/10/26 2:27:03 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Leadership Updates

    Live Leadership Updates

    View All

    Old Spice Teams Up With Iconic R&B Group to Ignite Beloved "Mom Song" in New Campaign: 'The End of Adolescents'

    Old Spice, the iconic brand dedicated to the journey from boyhood to manhood, has launched its revitalized "Mom Song" campaign, 'The End of Adolescents.' Old Spice licensed the song ‘End of the Road' by the legendary R&B group, Boyz II Men. The campaign brings back the universally relatable experience of moms grappling with their sons' newfound manliness, a theme that was first introduced by Old Spice over a decade ago in the original, "Mom Song." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310541215/en/Old Spice Remixes the Classic R&B ‘Mom Song' to Launch Swagger Signature Scent Control The new 60-second spot takes the p

    3/10/26 8:06:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Spruce Weed & Grass Killer Lets One More Dog Out of the House

    Introducing Bruce, the Newest Mascot Joining the P&G Family After famously solving one of pop culture's greatest mysteries by unveiling "Spruce Let The Dogs Out," Spruce Weed & Grass Killer is ready to unleash its next big move. Today, the P&G Ventures brand is expanding its pack with the introduction of a new mascot: Bruce the Spruce Dog! This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302493134/en/Spruce Weed & Grass Killer Introduces Mascot; Meet Bruce the Spruce Dog Bruce the Spruce dog is here to change the weed control game by proving it is the ultimate pet friendly and weed deadly option. As the first and only mascot

    3/2/26 10:06:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Old Spice's Most Sophisticated Cologne-Infused Scents Arrive Nationwide: Introducing the Spice Alchemist Collection

    Old Spice's New Premium Line is Crafted for Compliments with Scents Preferred Versus $300 Colognes Old Spice continues to redefine men's grooming with the Spice Alchemist collection, merging the artistry of a premium fine fragrance with cologne-infused scents and the brand's legendary, high-performance odor protection. This lineup embodies premium fragrances with scents that are preferred versus a $300 cologne in blind consumer testing, but at a fraction of the cost. Yes, you can have it all. Old Spice, the Greatest Smell in the NFL, will give fans a "sneak sniff" of Spice Alchemist at the "Unrivaled Freshness Experience" at Super Bowl LX in San Francisco, and the new lineup will continue

    2/4/26 8:06:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Financials

    Live finance-specific insights

    View All

    P&G Declares Quarterly Dividend, July 2026

    The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0885 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after August 17, 2026 to Common Stock shareowners of record at the close of business on July 24, 2026, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on July 24, 2026. P&G has been paying a dividend for 136 consecutive years since its incorporation in 1890 and has increased its dividend for 70 consecutive years. This reinforces our commitment to return cash to shareowners, many of who

    7/14/26 4:15:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Announces Fiscal Year 2026 Third Quarter Results

    Net Sales +7%; Organic Sales 3% Diluted EPS $1.63, +6%; Core EPS $1.59, +3% MAINTAINS FISCAL YEAR SALES, EPS GROWTH AND CASH RETURN GUIDANCE The Procter & Gamble Company (NYSE:PG) reported third quarter fiscal year 2026 net sales of $21.2 billion, an increase of seven percent versus the prior year. Organic sales, which excludes the impacts of foreign exchange and acquisitions and divestitures, increased three percent versus the prior year. Diluted net earnings per share were $1.63, an increase of six percent versus prior year, driven by a gain from the dissolution of the Glad joint venture business. Core earnings per share were $1.59, an increase of three percent versus prior year.

    4/24/26 7:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Declares Dividend Increase for April 2026

    The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared an increased quarterly dividend of $1.0885 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after May 15, 2026 to Common Stock shareowners of record at the close of business on April 24, 2026, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on April 24, 2026. This represents a three percent increase compared to the prior quarterly dividend. P&G has been paying a dividend for 136 consecutive years since its incorporation in 1890 and has increased its dividend for 70

    4/14/26 4:15:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/22/24 4:50:46 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/9/24 2:20:54 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/2/24 3:44:23 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care